SynthesisFrontiers in immunology2022
Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
Synthesis in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- The potential effects, mechanisms and translational perspectives of natural products in the treatment of atopic dermatitis.Chinese medicine · 2026Review
- Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic Innovation.International journal of molecular sciences · 2026Review
- Atopic dermatitis.Nature reviews. Disease primers · 2026Review
- Analysis of correlated factors of skin pruritus in type 2 diabetes mellitus.BMC endocrine disorders · 2026Observational
- Advancing Therapeutic Strategies in Atopic Dermatitis: Emerging Targets and Personalized Approaches.Biomolecules · 2025Review
- Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives.Journal of clinical medicine · 2025Review
- Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review.Dermatology and therapy · 2024Review
- A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis.Journal of clinical medicine · 2024Review
- Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review.Dermatology and therapy · 2024Review
- Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors.American journal of clinical dermatology · 2024Review
- The role of nemolizumab in the treatment of atopic dermatitis for the adult population.Immunotherapy · 2024Review
- Novel insights into atopic dermatitis.The Journal of allergy and clinical immunology · 2023Review
- Pruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis.Journal of clinical medicine · 2023Review
- Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis.Pharmaceutics · 2023Review
- The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update.Frontiers in molecular biosciences · 2023Review
- High Serum IL-31 Concentration Is Associated with Itch among Renal Transplant Recipients.Journal of clinical medicine · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nemolizumab is deemed as a promising drug for atopic dermatitis (AD) patients with pruritus. Objective: This study aimed to evaluate the efficacy of nemolizumab in treating patients with AD and the association between the dosage or regimen of nemolizumab with the improvement in clinical indices. Methods and Materials: PubMed, Embase, and the Cochrane Library were searched for randomized controlled trials (RCTs) published from inception to August 2021. Results: A total of 14 cohorts of participants from six randomized controlled studies were included in the meta-analysis. Nemolizumab significantly reduced the pruritus VAS (WMD = -18.86, 95% CI: -27.57 to -10.15, Conclusion: Nemolizumab presented a promising effect based on the difference in the average change in pruritus VAS and EASI scores compared with placebo. The results indicated its efficacy in relieving pruritus and the severity of AD and improving patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.